Pan-Cancer Analysis Identifies Targets for Personalized Medicine

This post was originally published on this site

Original Post from GeneomeWeb

NEW YORK (GenomeWeb) – A team led by researchers at Baylor College of Medicine has uncovered a number of mutations in a pan-cancer analysis that it said could be used as targets for tailored treatments.

Using data from the Cancer Genome Atlas, the researchers examined molecular alterations affecting the PI3K/AKT/mTOR pathway in more than 11,000 cancers from 32 tumor types. The PI3K/AKT/mTOR pathway is a growth regulatory pathway that is often activated in cancer.

As the team reported yesterday in Cancer Cell, it used whole-genome sequencing, whole-exome sequencing, copy number, and proteomic data from TCGA to home in on molecular changes affecting the PI3K/AKT/mTOR pathway that are likely functional.

“PI3K is the most commonly mutated pathway in cancer that can be targeted by drugs,” co­author Gordon Mills, professor of medicine and immunology at MD Anderson Cancer Center, said in a statement. “Thus, understanding how the pathway and mutations in cancer affect the many different cancer lineages is important.”

The researchers gathered 11,219 human cancer cases — representing 32 major types of cancer — for which the TCGA had generated data using one or more molecular approaches.

The proteomic data gathered via reverse-phase protein arrays covered more than 7,600 samples from


Leave a comment

Your email address will not be published.